跳到主要內容

臺灣博碩士論文加值系統

(18.97.9.169) 您好!臺灣時間:2025/02/16 06:58
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:許景盛
研究生(外文):Ching-Sheng Hsu
論文名稱:慢性C型肝炎患者胰島素抗性、代謝和脂肪激素狀態:病例對照研究與致病機轉探討
論文名稱(外文):Insulin resistance, metabolic and adipokine profiles inchronic hepatitis C patients:Case-control study and mechanistic exploration
指導教授:高嘉宏高嘉宏引用關係
指導教授(外文):Jia-Horng Kao
口試委員:林憲宏余明隆張明富
口試日期:2010-12-09
學位類別:博士
校院名稱:國立臺灣大學
系所名稱:臨床醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2010
畢業學年度:99
語文別:中文
論文頁數:209
中文關鍵詞:單核苷單核苷單核苷單核苷單核苷單核苷單核苷單核苷
外文關鍵詞:hepatitis C viruschronic hepatitis Cinsuin resistancelipid metabolismadipokinessustained virologic responsesingle nucleotide polymorphism
相關次數:
  • 被引用被引用:1
  • 點閱點閱:370
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
C型肝炎病毒感染一直是全球公共衛生上的重要課題。根據世界衛生組織的估計,全球目前至少有一億八千萬以上的人遭到C肝病毒的感染。就C肝病毒感染的自然史而言,急性C肝病毒感染後有百分之五十五到八十五的人會變成為慢性的C肝病毒感染。這些慢性C肝病毒感染者中有七成在10年後變成慢性C型肝炎的患者,變成慢性C型肝炎的患者中,有近兩成的人在20年後會產生肝硬化。在肝硬化的C肝患者中,每年有百分之一到四的風險產生肝癌,百分之四到五的風險肝臟衰竭。
慢性C肝病毒感染治療的主要目標為永久消滅病毒,也就是持續追蹤檢驗C肝患者時仍檢測不到血清C肝病毒的核醣核酸。臨床上稱這些人為達到持續病毒學反應(sustained virologic response, SVR),就是病毒學上的C肝治癒(cure)。然而C肝病毒感染治療的終極目標為希望使C肝患者的肝臟組織學及臨床的相關參數能夠進步,一方面能減緩肝臟組織纖維化的進展及肝硬化產生,另一方面則希望能夠防止肝臟衰竭與肝癌的發生。
目前臨床上已有許多C肝病程進展以及干擾素治療的預測因子可以評估患者未來的預後以及接受治療後的反應,這些因素主要分為兩大類,一類是與病毒相關的因子,另一類則是與宿主(host)相關的因子,利用這些預測因子吾人將可以給予病人個人化的C肝追蹤及治療。與病毒相關的預測因子中,除了治療前的C肝病毒量與病毒基因型外,評估C肝患者接受治療時的C肝病毒量變化為目前臨床上預測患者SVR的重要參考指標。值得注意的是,最近許多臨床及實驗室研究皆指出,C肝病毒感染與宿主的葡萄糖代謝、脂質代謝及肝臟脂肪變性有密切的關係存在,宿主的代謝特徵會影響C肝患者的抗病毒治療效果。因此清楚了解C肝病毒感染與宿主葡萄糖代謝及脂質代謝的關係已經成為現今全球肝病研究中的熱門課題。
因此吾人研究的主要目標為釐清C肝病毒感染對葡萄糖代謝與脂肪代謝的影響,並且探討脂肪變性、胰島素抗性、以及脂肪細胞激素與C肝病毒感染的關係。找尋影響C肝病態生理機轉的可能標的,進而改善未來C肝患者臨床預後與治療。
因此在臨床研究部分,吾人首先比較C肝患者及健康成人在血清中代謝特徵的差異性。吾人發現,C肝患者會較健康成年人有較高的血清高密度脂蛋白膽固醇(high-density lipoprotein-cholesterol, HDL)、脂締素(adiponectin)濃度、但是較低的總膽固醇、三酸甘油酯與低密度脂蛋白膽固醇(low-density lipoprotein-cholesterol, LDL)濃度值。進一步比較C肝患者血清中代謝特徵與抗病毒治療效果時亦發現,C肝患者接受干擾素相關治療時的早期病毒量下降程度與身體質量指標(BMI)以及血清中的HDL 濃度有關。此外吾人亦發現血清中的C肝病毒量與血清中胰島素及三酸甘油酯濃度間存有正比例的關係,並且血清中C肝病毒量與宿主脂肪代謝特徵的關係會隨著C肝病毒基因型的不同而不同。進一步的研究更發現,雖然宿主的代謝特徵會影響C肝患者肝臟組織的纖維化,然而這個影響作用也會因不同C肝病毒基因型的感染而產生不一樣的效果。
另一方面,幾個重要的研究團隊最近共同指出,與介白質28B(interleukin 28B, IL28B, 合成interferon-λ3)相關之單核苷酸多形性(single nucleotide polymorphism, SNP)和C肝患者接受干擾素抗病毒藥物的治療效果間存有強烈的關聯性。因此吾人進一步研究C肝患者血清脂肪代謝特徵與IL28B SNP的關係性。初步的研究發現,帶有IL28B SNP rs8099917 的TT 基因型患者除了會較GT基因型患者在接受標準長效型干擾素治療後有較高的SVR外,TT 基因型患者也較GT基因型患者在接受治療前有較低的血清中三酸甘油酯濃度。
實驗室研究方面,吾人利用能表現不同濃度C肝基因型第一型病毒核心蛋白(HCV core protein)的肝癌細胞株(Huh 7-based cell lines)來分析宿主脂肪與膽固醇合成途徑上重要基因的表現。研究發現,表現C肝基因型第一型病毒核心蛋白的細胞較控制組有較低的細胞內三酸甘油酯與膽固醇濃度。此外不同濃度的C肝病毒核心蛋白對於細胞內膽固醇與脂肪酸製造途徑上的基因表現可以產生不同的影響,表現C肝基因型第一型病毒核心蛋白的細胞較控制組細胞,在3-羥基-3-甲基戊二酸單醯輔酶A合成酶 (3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) synthase)、還原酶(HMG-CoA reductase)以及微粒体三酸甘油酯轉移蛋白(microsomal triglyceride transfer protein, MTTP) 的mRNA表現量上都相對降低,但是在法尼基轉移酶1 (farnesyl-diphosphate farnesyltransferase 1, FDFT1)與ATP citrate lyase mRNA的表現量上則相對增加。C肝病毒核心蛋白低表現量細胞中SREBP1c的mRNA表現量為增加,但是其表現量會隨著C肝病毒核心蛋白量增加而逐漸下降。另外,表現C肝病毒核心蛋白的細胞較控制組在SREBP2 mRNA的表現量上相對增加,但是其表現量也會隨著C肝病毒核心蛋白量的增加而下降。

結語

醫學進步已使現今慢性C型肝炎病毒的感染成為一種可以治療、甚至治癒的疾病。目前臨床上依據不同的預測因子,包括C肝病毒基因型、治療中的病毒動力學變化以及宿主不同的單核苷酸多形性,已經可以給予患者更有效率與更少副作用的個人化治療。然而臨床因子對於C肝患者的自然病史以及抗病毒治療的影響,特別是宿主代謝因子對C肝患者干擾素治療的影響,以及背後的病態生理機轉,仍有待吾人累積更多的研究資料加以闡明。如果未來能夠對於宿主代謝因子與C肝病毒間之作用關係更加了解,吾人相信這些知識將能應用於臨床上,改善未來C肝患者的藥物治療方式,使其變得更有效率、副作用也更加減少。

Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis, liver cirrhosis, end-stage liver disease and hepatocellular carcinoma worldwide. About 55% to 85% HCV infected people will become chronic hepatitis, 5% to 20% of them will turn to liver cirrhosis after duration of 20 to 25 years, 30 % of these cirrhotic patients will become end stage liver disease in 10 years, and once cirrhosis is established, the risk of hepatocellular carcinoma is approximately 1% to 5 % per year. In Taiwan, about 2–4% Taiwanese people are chronic carriers of HCV; hence, effective tackling this virus is an important issue in Taiwan.
The goal of treating chronic hepatitis C (CHC) patients is to eradicate the virus or, in a clinical term, to attain a sustained virological response (SVR, defined as undetectable serum HCV RNA level 24 weeks after treatment cessation). However, currently approved pegylated interferon (Peg-IFN) plus ribavirin (RBV) therapy has many unpleasant side effects and is only effective in a certain proportion of patients with HCV genotype 1 (GT1) infection, especially in Western countries. Therefore, identifying baseline and on-treatment factors predictive of SVR in CHC patients is important in terms of increasing efficacy, avoiding unnecessary side effects and saving medical costs.
Several factors have been linked to the therapeutic response of CHC patients, including viral factors, host factors, metabolic factors, histological factors, the type of regimens, and the duration of infection. Among these factors, early viral kinetics following therapy has become increasingly recognized and widely used in both clinical trials and daily practice. On the other hand, there is increasing interest in the impact of chronic HCV infection on metabolic abnormalities, including glucose, lipid, cytokines, insulin resistance and adipokines. Insulin resistance and type 2 diabetes have inceased incidence in CHC patients than in other disease or chronic hepatitis B patients, and serum lipid profiles as well as hepatic steatosis are associated with HCV infection and may afftect the therapeutic response of CHC patients. Howevr, the interacions between HCV infection and host metabolism as well as the underlying mechanisms remained not fully clarified.
To examine the influence of hepatitis C virus infection on adipokines, glucose and lipid metabolism, we examine the underlying mechanisms by which HCV affects host adipokines, glucose and lipid metabolism, and vice versa, from both clinical and molecular points of views. We found CHC patients had higher alanine aminotransferase (ALT) and high-density lipoprotein-cholesterol levels, but lower total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol levels than controls. By using multiple linear regression analyses for subjects with available adiponectin data, presence of HCV infection was independently associated with higher serum adiponectin. In addition, we found body mass index and genotype were related to viral load decline at day 2, and baseline viral load and HDL level were correlated with viral load decline between day 2 and day 28 in multivariate analysis. Genotype 2, lower baseline viral load and more substantial viral load decline at day 28 predicted a higher SVR.
Recently, several groups have found that the genetic polymorphism near IL28B gene may predict the therapeutic response of CHC GT 1 infected patients receiving Peg-IFN plus RBV. Thus, it is important and will be informative to evaluate the association of genetic polymorphism near IL28B gene, SVR and metabolic profiles in CHC GT 1 infected patients. We found Taiwanese CHC patients with rs8099917 TT genotype have a better SVR and lower baseline serum TG level than subjects with GT gentype.
In the in vitro studies, we found that cells expressing HCV core proteins had lower cellular triglyceride and total cholesterol levels than controls (P<0.05, ANOVA; P<0.05, Nonparametric test for trend). HCV GT1 core proteins might down-regulate mRNA expressions of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) synthase, HMG-CoA reductase and microsomal triglyceride transfer protein, but up-regulate mRNA expressions of farnesyl-diphosphate farnesyltransferase 1and ATP citrate lyase. Although mRNA expression of SREBP1c was up-regulated under lower levels of HCV core proteins, its expression was down-regulated with increasing HCV core protein levels. The mRNA expression of SREBP2 was up-regulated by HCV core proteins, but down-regulated with the increasing HCV core protein levels.
CONCLUSIONS: HCV is a curable disease, and the evaluation of HCV genotype, viral kinetic parameters as well as host gene SNPs before treatment has let individualized therapies for CHC patients become possible approaches. However, the interactions and underlying mechanisms of host factors and HCV infection, especially glucose and lipid metabolsim as well as their impacts on therapeutic resposes, remain not fully understood. Further experimental and clinical studies based on these lines of evidence are needed to clearly clarify underlying mechanisms and provide clinicians useful information to opitimize the mangement of chronic HCV infection.

口試委員會審定書…………………………………………….. i
誌謝……………………………………………………………. ii
中文摘要………………………………………………………. viii
英文摘要……………………………………………………….. xii

壹、緒論…………………………………………………… 1
第一章 C肝病毒感染的自然病史以及臨床治療……………… 4
第一節 C型肝炎病毒感染的自然史…………………………… 4
第二節C肝患者的預後以及治療的目標……………….………… 5
第三節 慢性C型肝炎患者的標準治療方式……………………… 5
第四節 慢性C肝患者對干擾素相關治療反應的臨床預測指標… 7
第五節 干擾素相關治療後的病毒學反應評估指標…………… 8
第六節 C肝病毒動力學…………………………………………… 10
第七節 接受抗病毒藥物治療的適當對象……………………… 12
第八節 抗C肝病毒藥物治療的臨床評估………………………… 13
第二章 C肝病毒感染與宿主脂質及葡萄糖代謝的關係…………15
第一節、 宿主葡萄糖及脂質代謝與C肝病毒的密切關係……… 15
第二節、 C肝病毒感染與宿主葡萄糖代謝的關係……………… 15
2.1葡萄糖代謝與胰島素抗性的產生………………………… 15
2.2 糖尿病、胰島素抗性與C肝病毒感染……………………. 16
2.3 C肝病毒感染引起胰島素抗性與肝臟纖維化的可能原因 17
2.4 C肝病毒引起胰島素抗性的分子機轉………….…………. 18
第三節、C肝病毒感染與宿主脂質代謝的關係………….……. 23
3.1 肝臟脂肪變性……………………………………………… 23
3.2 脂肪性肝病與其他慢性肝臟疾病的交互作用………..… 24
3.3 肥胖導致之非酒精性脂肪肝病與胰島素抗性………….. 24
3.4肝臟脂肪變性、脂肪肝炎與肝臟纖維化………………… 26
3.5肝臟脂肪變性和慢性C肝患者肝臟纖維化進展………… 27
3.6脂肪代謝惡化C肝患者肝臟纖維化的可能機轉………… 29
3.7 肝臟脂肪變性減少的正面效應…………………………… 31
3.8 脂肪變性與抗病毒治療反應的關係……………………… 32
3.9 肥胖、肝臟脂肪變性與酒精性肝臟疾病………………… 32
3.10肝臟脂肪變性、肥胖與肝癌……………………………… 33
3.11肝臟脂肪變性與藥物性肝臟疾病………………………… 35
3.12肝臟脂肪變性與其他肝臟疾病…………………………… 35
第四節、宿主基因多形性變異與新型抗C肝病毒藥物………… 37
4.1 介白質28B基因多形性與C肝病毒感染的相關性……… 37
4.2 IL28B基因的角色……................ ........... 39
4.3 新型抗C肝病毒治療藥物………………………………… 40
第五節、研究的問題及其重要性…………………….......... 40
第六節、研究的假說與特定目的………………............. 41

貳、研究方法與材料………………....................... 43
一、葡萄糖代謝及脂肪代謝與C型肝炎病毒感染之相關性研究 43
1.1探討慢性C肝病毒感染與患者體內代謝特徵的關係性……… 43
1.2探討慢性C肝患者血清中病毒量與胰島素抗性的關係性….. 43
1.3探討慢性C肝患者血清中病毒量與宿主脂肪特徵的關係性… 44
1.4探討慢性C肝患者接受長效型干擾素合併雷巴威林治療後早期病毒動力學與各種臨床特徵的關係性……………………………. . 46
1.5探討不同C肝病毒基因型對患者代謝特徵與肝臟組織學關係的影響性………………………………………………………….….…… 47
二、 C肝病毒蛋白對葡萄糖及脂肪代謝訊息傳遞途徑的影響和機制.. 48
三、實驗材料及方法……………………………… 48

叁、結果…............................................ 54
一、葡萄糖代謝及脂肪代謝與C型肝炎病毒感染之相關性研究….54
1.1探討慢性C肝病毒感染與患者體內代謝特徵的關係性……... 54
1.2探討慢性C肝患者血清中病毒量與胰島素抗性的關係性….. 55
1.3探討慢性C肝患者血清中病毒量與宿主脂肪特徵的關係性… 56
1.4探討慢性C肝患者接受長效型干擾素合併雷巴威林治療後早期病毒動力學與各種臨床特徵的關係性………………………………... 58
1.5探討不同C肝病毒基因型對患者代謝特徵與肝臟組織學關係的影響性……………………………………………………………..……. 62
二、 C肝病毒蛋白對葡萄糖及脂肪代謝訊息傳遞途徑的影響和機制.. 64

肆、討論……………………………………………………… 65
伍、展望…………………………………………………………… 87
陸、論文英文簡述………………………………………………… 96
柒、參考文獻…………………………………………………………109
表1-32等……………………..………………………………. 148-184
圖1-15等………………………………………..……………. 185-205

附錄:列出個人在碩博士班修業期間所發表之相關論文清冊 206-209


1.Seeff LB. Natural history of chronic hepatitis C. Hepatology. Nov 2002;36(5 Suppl 1):S35-46.
2.Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 1995;25:27-32.
3.National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. Nov 2002;36(5 Suppl 1):S3-20.
4.Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. Dec 2003;362(9401):2095-2100.
5.Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. Dec 1992;327(27):1899-1905.
6.Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. Aug 1999;341(8):556-562.
7.Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. Jul 2000;32(1):91-96.
8.Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. The New England journal of medicine. Apr 1999;340(16):1228-1233.
9.Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. Sep 1999;341(12):866-870.
10.Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. Jun 1995;332(22):1463-1466.
11.Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. Jun 1996;23(6):1334-1340.
12.Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. Oct 1999;30(4):1054-1058.
13.Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. Mar 1997;349(9055):825-832.
14.Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. May 1998;27(5):1435-1440.
15.Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. Dec 1998;28(6):1687-1695.
16.Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. Apr 2009;49(4):1335-1374.
17.Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. Sep 2001;358(9286):958-965.
18.Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. Sep 2002;347(13):975-982.
19.Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. Mar 2007;27(2):186-191.
20.Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. Mar 2004;140(5):346-355.
21.Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23 Suppl 1:23-28.
22.Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. Nov 2004;20(9):931-938.
23.Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. Dec 2007;46(6):1732-1740.
24.Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol. May 2008;103(5):1131-1135.
25.Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. Aug 1997;113(2):558-566.
26.Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. Apr 1998;27(4):1149-1156.
27.Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. Mar 1997;25(3):745-749.
28.Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. Mar 2003;37(3):600-609.
29.Missiha S, Heathcote J, Arenovich T, Khan K. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. Oct 2007;102(10):2181-2188.
30.Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. Sep 2003;38(3):639-644.
31.Akuta N, Suzuki F, Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol. Apr 2005;75(4):550-558.
32.Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. Apr 2004;39(4):1147-1171.
33.Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat. Mar 1996;3(2):85-96.
34.Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther. 2009;14(1):45-54.
35.Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. Mar 2005;128(3):636-641.
36.Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. Sep 2003;38(3):645-652.
37.Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. Jun 2007;22(6):832-836.
38.Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. May 2006;43(5):954-960.
39.Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. Sep 2005;43(3):425-433.
40.Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. Jul 2007;357(2):124-134.
41.Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. Jan 1995;373(6510):123-126.
42.Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. Jan 1995;373(6510):117-122.
43.Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. May 1997;387(6629):188-191.
44.Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. Oct 1998;282(5386):103-107.
45.Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. Apr 1996;93(9):4398-4402.
46.Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. Jun 1999;29(6):1863-1869.
47.Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology. Oct 2005;42(4):749-754.
48.Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology. Feb 1996;23(2):366-371.
49.Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther. Jun 2000;5(2):85-90.
50.Layden JE, Layden TJ. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology. Apr 2002;35(4):967-970.
51.Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. Jun 2003;37(6):1351-1358.
52.Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat. May 2008;15(5):379-382.
53.Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. Apr 2002;35(4):930-936.
54.Thiebaut R, Guedj J, Jacqmin-Gadda H, et al. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol. 2006;6:38.
55.Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry. Jan 1965;12:63-70.
56.Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. Apr 1979;134:382-389.
57.Pradat P, Tillmann HL, Sauleda S, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat. Aug 2007;14(8):556-563.
58.Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. Nov 2007;147(10):677-684.
59.Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. Nov 2005;42(5):1208-1236.
60.Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat. Jul 2009;16(7):479-484.
61.Romero-Gomez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. Dec 2009;50(6):1702-1708.
62.Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. Mar;30(3):447-454.
63.Ratziu V, Saboury M, Poynard T. Worsening of steatosis and fibrosis progression. Gut. Sep 2003;52(9):1386-1387.
64.Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. Dec 2003;125(6):1695-1704.
65.Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. May 2004;39(5):1239-1247.
66.Dixon JB, Bhathal PS, O''Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. Jul 2001;121(1):91-100.
67.Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. Jun 2005;2(6):273-280.
68.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. Apr 2005;365(9468):1415-1428.
69.Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. Nov 2005;42(5):987-1000.
70.Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med. Jun 2005;22(6):674-682.
71.Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. Qjm. Jan 2005;98(1):1-6.
72.Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. Oct 2000;133(8):592-599.
73.Wilson C. Hepatitis C infection and type 2 diabetes in American-Indian women. Diabetes Care. Sep 2004;27(9):2116-2119.
74.Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. Aug 2001;35(2):279-283.
75.Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care. May 2004;27(5):1171-1175.
76.Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract. Mar 2007;75(3):320-326.
77.Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. May 2006;43(5):1168; author reply 1168-1169.
78.Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. Feb 2004;126(2):586-597.
79.Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. Mar 2004;126(3):840-848.
80.Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. Jun 1999;29(6):1743-1751.
81.Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. Oct 2001;34(4 Pt 1):738-744.
82.Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. Dec 2003;39(6):1049-1055.
83.Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol. Dec 2003;39(6):1042-1048.
84.Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. Jul 2007;47(1):142-156.
85.Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. Oct 2006;113(10):1141-1147.
86.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. Dec 14 2006;444(7121):840-846.
87.Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. Jun 2002;32 Suppl 3:24-34.
88.Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol. May 1999;94(5):1332-1340.
89.Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol. Feb 1999;30(2):185-191.
90.Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. Nov 1997;272(47):29911-29918.
91.Valenti L, Pulixi E, Fracanzani AL, et al. TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol. Dec 2005;43(6):944-950.
92.Cooney RN. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock. Feb 2002;17(2):83-90.
93.Rico-Bautista E, Flores-Morales A, Fernandez-Perez L. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. Dec 2006;17(6):431-439.
94.Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. Dec 25 1998;273(52):35056-35062.
95.Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. Apr 2006;55(4):529-535.
96.Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. Dec 2001;276(51):47944-47949.
97.Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology. Oct 2007;46(4):1009-1015.
98.Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. Dec 2003;38(6):1384-1392.
99.Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. May 2007;45(5):1164-1171.
100.Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. Jul 2004;40(1):46-54.
101.Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. Dec 2005;100(12):2717-2723.
102.Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. Apr 2005;90(4):2240-2243.
103.Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. Nov 2006;24(9):1349-1357.
104.Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. Jul 2007;46(1):66-73.
105.Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: A New Independent Predictor of Liver Steatosis and Response to IFN-alpha Treatment in Chronic Hepatitis C. Am J Gastroenterol. Jan 11 2008.
106.Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. May 15 2007;25(10):1181-1191.
107.Romero-Gomez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol. May 2003;98(5):1135-1141.
108.Crespo J, Rivero M, Fabrega E, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci. Jul 2002;47(7):1604-1610.
109.Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat. Jan 2004;11(1):91-96.
110.Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. Dec 1994;21(6):1135-1139.
111.Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. Jan 2004;126(1):263-277.
112.Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. Apr 18 2002;346(16):1221-1231.
113.Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. Jul 2005;42(1):5-13.
114.Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology. May 2006;130(6):1848-1852.
115.Day CP. From fat to inflammation. Gastroenterology. Jan 2006;130(1):207-210.
116.Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. Feb 2006;43(2 Suppl 1):S99-S112.
117.Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. Apr 2004;40(4):578-584.
118.Jan CF, Chen CJ, Chiu YH, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond). May 2006;30(5):794-799.
119.Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. Sep 2004;38(8):705-709.
120.Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. Oct 2003;163(4):1301-1311.
121.Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. Mar 2001;33(3):738-750.
122.Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol. May 2002;160(5):1705-1715.
123.Ezure T, Sakamoto T, Tsuji H, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol. May 2000;156(5):1627-1639.
124.Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. Apr 2005;41(4):809-818.
125.Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. Jul 2002;51(1):89-94.
126.Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. Mar 2004;53(3):413-419.
127.Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. Jul 2003;38(1):75-85.
128.Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. Mar 2004;40(3):484-490.
129.Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci. Jan 1997;42(1):178-185.
130.Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. Oct 2007;46(4):982-990.
131.Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. Oct 2008;48(4):1033-1043.
132.Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. Aug 2007;46(2):371-379.
133.Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. Jul 2008;135(1):111-121.
134.Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. Nov 2004;127(5 Suppl 1):S97-103.
135.Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. Jul 2002;36(1):150-155.
136.El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. Feb 2004;126(2):460-468.
137.Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. Jun 2006;43(6):1295-1302.
138.Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. Jul 2002;123(1):134-140.
139.Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. Jun 2002;35(6):1485-1493.
140.Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. Jun 2003;97(12):3036-3043.
141.Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. Jun 2001;61(11):4365-4370.
142.Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. Feb 2002;122(2):352-365.
143.Kato T, Miyamoto M, Date T, et al. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci. Aug 2003;94(8):679-685.
144.Yang S, Koteish A, Lin H, et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology. Feb 2004;39(2):403-411.
145.Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis. 1999;19(3):243-252.
146.Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. Oct 2009;461(7265):798-801.
147.Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. Sep 2009;461(7262):399-401.
148.Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. Oct 2009;41(10):1100-1104.
149.Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. Oct 2009;41(10):1105-1109.
150.Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. Aug 2006;131(2):470-477.
151.Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. Jan 2003;4(1):69-77.
152.Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. Jan 2003;4(1):63-68.
153.Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. Dec 2006;131(6):1887-1898.
154.Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. Mar 2005;79(6):3851-3854.
155.Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. Feb 2005;174(4):1932-1937.
156.Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. Jun 1995;22(6):696-699.
157.Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. Jan 1997;35(1):201-207.
158.Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods. Apr 2007;141(1):1-6.
159.Kato N, Yoshida H, Ono-Nita SK, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. Aug 2000;32(2):405-412.
160.Nowak M, Swietochowska E, Marek B, et al. Changes in lipid metabolism in women with age-related macular degeneration. Clin Exp Med. Mar 2005;4(4):183-187.
161.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. Jul 1985;28(7):412-419.
162.Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. Sep 2007;46(3):912-921.
163.Huang KC. Obesity and its related diseases in Taiwan. Obes Rev. Mar 2008;9 Suppl 1:32-34.
164.Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. Sep;52(3):864-874.
165.Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. Sep;52(3):854-863.
166.Jarmay K, Karacsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol. Nov 2005;11(41):6422-6428.
167.Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. Oct 2009;50(4):1030-1037.
168.Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007;50(4):310-315.
169.Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res. Jan;40(1):69-82.
170.Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology. Apr 1992;15(4):567-571.
171.Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. Feb 1999;29(2):328-333.
172.White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. Journal of hepatology. Nov 2008;49(5):831-844.
173.Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. Jul 2004;40(1):177-184.
174.Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol. Aug 2005;43(2):235-242.
175.Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. Dec 2005;43(6):929-936.
176.Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. Jun 2003;423(6941):762-769.
177.Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol. Jun 2005;288(6):L1146-1153.
178.Yamaguchi A, Tazuma S, Nishioka T, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci. Jul 2005;50(7):1361-1371.
179.Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. Apr 2002;35(4):937-946.
180.Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol. Feb 2006;44(2):253-261.
181.Lu JY, Chuang LM, Yang WS, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int. Aug 2005;25(4):752-759.
182.Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. Feb 2005;128(2):334-342.
183.Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. Jan 2006;43(1):64-71.
184.Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. Jun 2001;33(6):1358-1364.
185.Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. Jul 2005;54(7):1003-1008.
186.Liu CJ, Jeng YM, Chen PJ, et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther. 2005;10(3):405-415.
187.Favre D, Muellhaupt B. Potential cellular receptors involved in hepatitis C virus entry into cells. Lipids Health Dis. Apr 2005;4(1):9.
188.Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS pathogens. Aug 2007;3(8):e108.
189.von Hahn T, Rice CM. Hepatitis C virus entry. J Biol Chem. Feb 2008;283(7):3689-3693.
190.Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem. Mar 4 2005;280(9):7793-7799.
191.von Hahn T, Lindenbach BD, Boullier A, et al. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology. May 2006;43(5):932-942.
192.Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology. Mar 1999;29(3):904-907.
193.Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. Aug 2006;44(2):335-340.
194.Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A. Feb 1997;94(4):1200-1205.
195.Prati D, Shiffman ML, Diago M, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. Apr 2006;44(4):679-685.
196.Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. Apr 2003;37(4):917-923.
197.Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. Dec 2006;44(6):1648-1655.
198.Rodriguez-Torres M, Govindarajan S, Sola R, et al. Hepatic steatosis in HCV/HIV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study. J Hepatol. May 2008;48(5):756-764.
199.Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. May 2006;130(6):1661-1669.
200.Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. Sep 2007;9(9):1089-1097.
201.Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. Feb 2008;28(2):271-277.
202.Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. Jun 2008;47(6):2127-2133.
203.Sterling RK, Contos MJ, Smith PG, et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. Apr 2008;47(4):1118-1127.
204.Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. May 2006;130(6):1636-1642.
205.Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. Feb 2008;134(2):416-423.
206.Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ. Jan 2003;10 Suppl 1:S59-67.
207.Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. Feb 2004;126(2):529-540.
208.Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. May 2008;48(5):721-727.
209.Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. Jan 2006;55(1):123-130.
210.Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. Sep 2008;48(3):723-731.
211.Sugimoto R, Enjoji M, Kohjima M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int. Oct 2005;25(5):1018-1026.
212.Jonsson JR, Barrie HD, O''Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. Jul 2008;48(1):80-87.
213.Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. May 2005;12(3):283-291.
214.Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. Oct 1999;96(22):12766-12771.
215.Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. Jul 2002;76(14):6919-6928.
216.Ludewig B, Jaggi M, Dumrese T, et al. Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol. Mar 2001;166(5):3369-3376.
217.Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat. Jan 2003;10(1):16-22.
218.Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. Nov 2006;107(9):2212-2222.
219.Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. Mar 2007;46(3):403-410.
220.Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. Jan 2008;46(1):78-84.
221.Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. Nov 2007;79(11):1686-1695.
222.Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. Apr 2007;56(4):553-559.
223.Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. Sep;52(3):822-832.
224.Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J. Feb 2002;16(2):185-194.
225.Chang ML, Yeh CT, Chen JC, et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics. 2008;9:109.
226.Nakamuta M, Yada R, Fujino T, et al. Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med. Dec 2009;24(6):825-828.
227.Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. Nov 2002;99(24):15669-15674.
228.Hsu CS, Liu CJ, Liu CH, et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int. Jun 2008;2(2):250-257.
229.Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A. Dec 2003;100(26):15865-15870.
230.Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. Feb 2005;102(7):2561-2566.
231.Chen DS, Wang JT, Chen PJ, Wang TH, Sung JL. Hepatitis C virus infection in Taiwan. Gastroenterol Jpn. Jul 1991;26 Suppl 3:164-166.
232.Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. Jun 2008;47(6):1884-1893.
233.Liu CH, Liu CJ, Lin CL, et al. Pegylated Interferon-alpha-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. Clin Infect Dis. Nov 2008;47(10):1260-1269.
234.Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. Mar 2004;140(5):370-381.
235.Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. J Hepatol. 2008;48 (Suppl. 2):5A.
236.Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. Dec 2004;40(6):1260-1265.
237.Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. Apr 2007;56(4):553-559.
238.Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. Mar 2010;464(7287):405-408.
239.Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. Jul 2006;44(1):117-125.
240.O''Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. Apr 2007;45(4):895-898.
241.Amemiya F, Maekawa S, Itakura Y, et al. Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis. Feb 2008;197(3):361-370.
242.Milazzo L, Caramma I, Mazzali C, et al. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother. Apr 2010;65(4):735-740.
243.Sezaki H, Suzuki F, Akuta N, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology. 2009;52(1):43-48.
244.Fujita N, Kaito M, Kai M, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat. Jul 2006;13(7):441-448.
245.Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol. Aug 2008;49(2):295-298.
246.Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. Mar 2010;30(3):447-454.
247.Hotamisligil GS. Inflammation and metabolic disorders. Nature. Dec 2006;444(7121):860-867.
248.Mangia A, Schiavone G, Lezzi G, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. Dec 1998;93(12):2363-2367.
249.Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. Oct 1999;30(4):1059-1063.
250.Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. Apr 2000;75(4):355-359.
251.Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol. Feb 2003;98(2):438-441.
252.Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. Jan 2005;100(1):48-55.
253.Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. Oct 2005;28(10):2548-2550.
254.Siagris D, Kouraklis-Symeonidis A, Christofidou M, et al. Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection. Eur J Gastroenterol Hepatol. Mar 2005;17(3):345-350.
255.Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. Jan 2006;13(1):56-61.
256.Behrendt CE, Ruiz RB. Hyperglycemia among persons with hepatitis C: not the classical diabetic phenotype. Diabetes Res Clin Pract. Jan 2006;71(1):68-74.
257.Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol. May 2003;98(5):1150-1154.
258.Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. Mar 2001;34(3):428-434.
259.Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta. May 1997;261(2):159-165.
260.Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes. Apr 2004;53(4):1150-1157.
261.Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. Mar 2002;13(2):84-89.
262.Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. The American journal of gastroenterology. Dec 2006;101(12):2752-2759.
263.Muzzi A, Leandro G, Rubbia-Brandt L, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. Journal of hepatology. Jan 2005;42(1):41-46.
264.Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. Jan 2007;45(1):80-87.
265.Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. Journal of acquired immune deficiency syndromes. Jul 2001;27(3):245-250.
266.Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology. Jul 2004;40(1):19-22.
267.Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. Dec 2003;125(6):1796-1807.
268.Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. Journal of hepatology. Jul 2004;41(1):19-24.
269.Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol. May 2000;15 Suppl:E91-96.
270.Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. Nov 2002;36(5 Suppl 1):S237-244.
271.Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. Jul 2003;38(1):50-56.
272.Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology. Jul 2004;324(2):450-461.
273.Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of hepatology. Jul 2000;33(1):106-115.
274.Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther. Aug 2006;24(3):507-512.
275.Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. Feb 2006;113(6):898-918.
276.Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. Feb 2008;15(2):129-136.
277.Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci. Oct 2007;105(2):145-150.
278.Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. Apr 2006;130(4):1098-1106.
279.Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. Mar 2004;53(3):451-455.
280.Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. Jan 2008;47(1):43-50.
281.Petta S, Camma C, Marco VD, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. May 2008;103(5):1136-1144.
282.Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. Sep 2003;98(9):2064-2071.
283.Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. Jun 2008;47(6):1856-1862.
284.Mallat A, Preaux AM, Blazejewski S, Dhumeaux D, Rosenbaum J, Mavier P. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology. Dec 1994;20(6):1589-1594.
285.Hsu CS, Liu CJ, Liu CH, et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int. 2008;2(2):250-257.
286.Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. Nov 2007;46(5):1350-1356.
287.Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. Sep 1997;26(3 Suppl 1):122S-127S.
288.Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology. Nov 1997;113(5):1647-1653.
289.Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology. Nov 2006;44(5):1146-1157.
290.Ebeling F, Lappalainen M, Vuoristo M, et al. Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response. Am J Gastroenterol. Apr 2001;96(4):1237-1242.
291.Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. Jul 2007;46(1):37-47.
292.Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. Jun 2003;37(6):1343-1350.
293.Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS. Jan 2004;18(1):59-66.
294.Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. Sep 2010;52(3):854-863.
295.Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology. Nov 2002;36(5):1266-1272.
296.Koike K, Tsutsumi T, Yotsuyanagi H, Moriya K. Lipid metabolism and liver disease in hepatitis C viral infection. Oncology. Jul;78 Suppl 1:24-30.
297.Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol. Aug 2007;81(15):8122-8130.
298.Ryan MC, Desmond PV, Slavin JL, Congiu M. Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. J Viral Hepat. Feb 2010.
299.Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. Mar 2009;104(3):598-604.
300.McPherson S, Jonsson JR, Barrie HD, O''Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol. Dec 2008;49(6):1046-1054.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 7. 吳重禮、黃綺君,〈必要之惡?從McCain-Feingold 法案看政治行動委員會的功能與影響〉,《政治科學論叢》,第十五期,2001年12月。
2. 9. 張世熒,行政院「政治獻金管理條例草案」評析,中國行政評論,第十二卷第三期,2003年6月。
3. 10. 張世賢,競選經費公費補助之研究,政治學報第十七期,中國政治學會,1989年12月。
4. 6. 吳東野,從德日經驗觀察行政院版的政治獻金管理條例,國家政策論壇,2003年8月。
5. 5. 江炳倫,我國競選經費現狀調查,中國論壇,第十四卷第一期,1982年4月
6. 4. 李惠宗,德國政治獻金制度之研究,美歐月刊,第九卷第六期,1994年6月。
7. 2. 朱雲鵬,政商掛勾與利益輸送,中國論壇,第三十一卷第十期,1991年7月。
8. 1. 朱志宏,政治資金的問題與對策,國家政策季刊,第三期,1989年9月。
9. 8. 沈玄池,德國政黨經費來源之研究,中央研究院歐美研究季刊,第23卷第一期,1993年3月。
10. 13. 許介鱗,日本新選舉制度對民主政治的影響,研考雙月刊,第21卷1期,1997年2月。
11. 14. 黃錦堂,政治獻金管理法案之評估,植根雜誌,第十九卷第二期,2003年。
12. 15. 黃錦堂,政治獻金法之釋義與評價,月旦法學雜誌,2004年7月。
13. 18. 黃世鑫,1994年德國政黨財源改革法:他山之石,經社法制論叢,第17卷第18期,1996年6月。
14. 21. 郭秋慶,西德政黨財政法與期變革,思與言,第25卷第1期,1987年5月。
15. 24. 謝文啟,政治捐獻與法律規制,全國律師,第一卷第十二期,1997年。